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Abstract. Background/Aim: Trabectedin is a DNA-
damaging agent and has been approved for the treatment of
patients with advanced soft tissue sarcoma. Schlafen 11
(SLFN11) was identified as a dominant determinant of the
response to DNA-damaging agents. The aim of the study was
to clarify the association between SLFN11 expression and
the antitumor activity of trabectedin. Materials and Methods:
The antitumor activity of trabectedin was evaluated under
different expression levels of SLFN11 regulated by RNA
interference and CRISPR-Cas9 systems, and the combined
antitumor activity of ataxia telangiectasia and Rad3-related
protein kinase (ATR) inhibitor and trabectedin in sarcoma
cell lines using in vitro a cell viability assay and in vivo
xenograft models. Results: SLFN11-knockdown cell lines had
a lower sensitivity to trabectedin, compared to parental cells.
ATR inhibitor enhanced the antitumor activity of trabectedin
in SLFN11-knockdown cells and in a SLFN11-knockout
xenograft model. Conclusion: SLFN11 expression might be
a key factor in the antitumor activity of trabectedin.
Trabectedin (Yondelis®, ecteinascidin-743, ET-743) is a
marine-derived natural product that has been approved for
the treatment of patients with advanced soft tissue sarcoma
and relapsed platinum-sensitive ovarian cancer in
combination with liposomal doxorubicin (1, 2). Ongoing
studies suggest that trabectedin is also effective against other
solid malignancies, including breast cancer (3).
Previous studies have shown a peculiar aspect of the
mechanism of action of trabectedin. Trabectedin showed a
decreased activity (from 2- to 10-fold) in nucleotide excision
repair (NER)-deficient cells, compared to NER-proficient
cells (4, 5). DNA-bound trabectedin is thought to prevent the
correction of DNA lesions through transcription-coupled
NER (TC-NER) by creating cytotoxic ternary complexes
with DNA-binding proteins of the NER system, such as
XPG. On the other hand, NER-deficient cells show an
increased sensitivity to platinum drugs, such as cisplatin (4-
6). Homologous recombination repair (HRR) has been
shown to be important for trabectedin, since HRR-deficient
cells were 50- to 100-times more sensitive to trabectedin (7,
8). The lack of HRR has been associated with the persistence
of unrepaired DNA double-strand breaks (DSBs) during the
S phase of the cell cycle and apoptosis (7). Moreover, the
inhibition of the cell-cycle checkpoints that are activated in
response to trabectedin might also prove useful to increase
drug efficacy (9, 10). In response to replicative damage,
ataxia telangiectasia and Rad3-related protein kinase (ATR)
plays a major role in coordinating cell-cycle progression and
DNA repair (11, 12). The loss of the S-phase checkpoint by
ATR inhibitors causes the unscheduled firing of replication
origins in S-phase and the induction of DSBs (13, 14). At
present, a total of 39 different gene fusions have been
identified in 15 different tumor types, accounting for
approximately 20% of all soft tissue sarcomas (15).
Furthermore, trabectedin interacts with fused genes and
inhibits the expressions of oncogenes, which are up-
regulated by gene fusions such as EWS-FLI1 and FUS-
CHOP (16, 17).
Recently, Schlafen 11 (SLFN11) was discovered during
bioinformatics analyses of cancer cell databases and was
identified as a dominant determinant of cell response to some
widely used anticancer drugs, including topoisomerase (Top)
1 inhibitors, Top2 inhibitors, alkylating agents, and DNA
synthesis inhibitors (18, 19). The importance of SLFN11 in
drug sensitivity has recently been extended to include
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Ewing’s sarcoma (20). SLFN11 influences the response of
patients with ovarian, non-small cell lung, or colorectal
cancers (18, 19), and inhibits checkpoint maintenance and
homologous recombination by removing replication protein
A (RPA) from single-stranded DNA (21). Recent reports
have shown that SLFN11 is recruited to stressed replication
forks carrying extended RPA filaments where it blocks
replication independently of HRR (22).
In this study, a correlation analysis comparing the
antitumor activity of trabectedin and SLFN11 expression in
sarcoma cell lines was performed and demonstrated the
importance of SLFN11 expression as a key factor in the
antitumor activity of trabectedin in sarcoma cell lines and
xenograft models. Furthermore, the usefulness of
combination therapies to overcome the decreased antitumor
activity of trabectedin in cells with low SLFN11 expression
levels was evaluated.
Materials and Methods
Cell lines. The human sarcoma cell lines Yamato-SS and Aska-SS
were kindly provided by Dr. Norifumi Naka (Osaka International
Cancer Institute, Osaka, Japan) and Dr. Kazuyuki Ito (Nozaki
Tokushukai Hospital, Osaka, Japan); SYO-1 was kindly provided by
Dr. Akira Kawai (National Cancer Center, Tokyo, Japan); HT-1080,
KYM-1, NY, RD, SCCH-196, RKN, SKN and HuO9N2 were
purchased from the Japanese Collection of Research Bioresources
(Osaka, Japan); Hs 925.T, KHOS/NP, KHOS-240S, SK-LMS-1,
KHOS-312H, SW 872, SW 982, MES-SA, U-2 OS, SK-ES-1, SJSA-
1, SJCRH30 and RD-ES were purchased from ATCC (Manassas, VA,
USA); ESS-1 was purchased from DSMZ (Brunswick, Germany);
and A673, HOS, MG-63, G-292 clone A141B1 and Saos-2 were
purchased from KAC Co., Ltd. (Kyoto, Japan). All the cells were
maintained according to the supplier’s protocols.
Chemicals. Trabectedin was provided by PharmaMar (Madrid,
Spain). VE-821 (http://www.selleckchem.com/products/ve-
821.html) was purchased from Selleck Chemicals (Houston, TX,
USA). Berzosertib (VE-822; https://www.medchemexpress.com/VE-
822.html) was purchased from MedChemExpress (Monmouth
Junction, NJ, USA). 5-Aza-2’-deoxycytidine (decitabine) was
purchased from Sigma-Aldrich Co., LLC (St. Louis, MO, USA).
Antibodies. Antibodies against SLFN11 (sc-374339), and CHK1 (sc-
8408) were obtained from Santa Cruz Biotechnology (Dallas, TX,
USA). Antibodies against phospho-Ser317-CHK1 (#2344),
phospho-Ser345-CHK1 (#2348), phospho-Ser139-H2AX (#9718),
and GAPDH (#2118) were obtained from Cell Signaling
Technology (Danvers, MA, USA). Horseradish peroxidase-
conjugated secondary antibodies to mouse or rabbit IgG were
obtained from Cell Signaling Technology.
Cell viability assay. Cell viability was measured using the crystal
violet staining method and CellTiter-Glo 2.0 Assay (Promega,
Fitchburg, WI, USA). Approximately 2-5×103 cells were plated per
well on a 96-well plate. The cells were treated with a range of drug
concentrations for 72 h. After adding the CellTiter-Glo reagent,
luminescence readings were obtained using a VersaMax Absorbance
Microplate Reader (Molecular Devices, San Jose, CA, USA) and
FlexStation3 (Molecular Devices). The 50% and 75% inhibitory
concentrations (IC50 and IC75) were calculated using an XLfit (Fit
model 205, ITOCHU Techno-Solutions Co., Tokyo, Japan).
Quantitative RT-PCR. For the TaqMan array cards and the TaqMan
gene expression assay (Thermo Fisher Scientific, Waltham, MA,
USA) experiments, RNA was collected from 30 sarcoma cell lines
using an RNeasy kit (Qiagen, Venlo, the Netherlands).
Complementary DNA (cDNA) was synthesized using High-Capacity
cDNA Reverse Transcription Kits (Thermo Fisher Scientific). The
reaction was carried out following the methods for use of TaqMan
Universal Master Mix Ⅱ (2×) (Thermo Fisher Scientific), and ACTB
and GAPDH were used as the reference genes.
siRNA transfection. Cells (1-3×105) were plated in 6-well plates.
The siRNA for human SLFN11 and negative control (Stealth RNAi
siRNA, HSS132188 and 12935300) were products of Invitrogen
(Carlsbad, CA, USA). siRNA (5 nmol/l) was transfected into each
cell with Lipofectamine RNAiMAX Reagent (Invitrogen) according
to the manufacturer’s instructions.
Western blotting. Total protein was extracted from whole cells using
a cellular protein extraction buffer containing protease and
phosphatase inhibitors. The protein contents were measured using a
Pierce® BCA Protein Assay Kit (Bio-Rad, Hercules, CA, USA).
Protein extracts were separated using SDS-PAGE polyacrylamide gels
and electroblotted onto a PVDF membrane (Bio-Rad). The blotted
membrane was blocked with Blocking One and Blocking One P
(Nacalai Tesque, Kyoto, Japan). The primary antibodies were diluted
in Can Get Signal Immunoreaction Enhancer Solution 1 (TOYOBO,
Osaka, Japan) at a 1:1,000 dilution for SLFN11, phospho-Ser317-
CHK1, phospho-Ser345-CHK1, CHK1, and phospho-Ser139-H2A.X
and a 1:5000 dilution for GAPDH. The secondary antibody (Cell
Signaling Technology) was diluted in Can Get Signal
Immunoreaction Enhancer Solution 2 at a 1:2,000 dilution. Signals
were detected by using a ChemiDoc Touch (Bio-Rad).
Establishment of SLFN11-knockout cells. To delete the SLFN11
gene, we used Edit-R CRISPR RNA (crRNA), which was designed
to target the human SLFN11 gene (CM-01674-01-0002 and CM-
01674-02-0002) (Dharmacon, Lafayette, CO, USA). crRNA, Edit-
R trans-activating CRISPR RNA, and SMARTCas9 (Puro®)
Expression Plasmid were co-transfected into SW 872 cells
according to the instruction manual. Approximately 1 week after
transfection, the cells were cultured in the presence of puromycin
(1.5-2.5 μg/ml). Approximately 3-4 weeks later, puromycin-resistant
clones were then selected and allowed to expand. A lack of SLFN11
protein expression in the SW 872 knockout cells was confirmed
using western blotting.
In vivo experiments. Five-week-old male BALB/c nude mice were
purchased from CLEA Japan, Inc. (Tokyo, Japan) and were housed
under specific pathogen-free conditions. Following a quarantine
period of about 1 week, tumor fragments (approximately 2 mm
diameter) were implanted subcutaneously via an implant needle in the
vicinity of the right hindmost rib of the nude mice. The length (mm)
and width (mm) were measured, and the tumor volume (TV, mm3)
for each fragment was calculated using the following formula:
TV=(length) × (width)2/2. When the TV reached 100-200 mm3, the
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mice were divided into groups using a stratified randomization
method so as to equalize the mean TV in each group. Each group
consisted of 6 nude mice. Trabectedin [0.01 mg/mL in a solution of
0.05 mol/l KH2PO4(pH4.0)] was administered by intraperitoneal
bolus injection on days 1, 5, and 9 at a dose of 0.1 mg/kg, which was
the maximum tolerated dose in nude mice. VE-822 [30 mg/kg in a
solution of 10% vitamin E tocopheryl polyethylene glycol succinate
(VitE TPGS)] was administered by oral gavage on days 1, 2 and 3 of
each 4-day cycle. The control group was treated with the vehicle
(0.05 mol/l KH2PO4, pH4.0) for trabectedin on days 1, 5, and 9. 
The TVs were measured twice a week until day 15. On day 15,
the tumor growth inhibition rate (TGI) was calculated using the
following formula: TGI=[1 – (mean TV of treated group)/(mean TV
of control group)] ×100. The body weight change (BWC, %) was
calculated as [(body weight on day 15) – (body weight on day
0)]/(body weight on day 0) ×100.
The animal study was conducted according to institutional
guidelines and was approved by the Institutional Animal Care and
Use Committee of Taiho Pharmaceutical Co., Ltd.
Statistical analysis. The correlation analysis for the antitumor
activity of trabectedin and the gene expression of SLFN11 was
performed using JMP (version 9) software (SAS Institute Inc., Cary,
NC, USA). The significance of the difference in the mean SLFN11
expression levels between the 2 groups (TRS vs. non-TRS) was
analyzed using the Aspin-Welch two-tailed t-test. Differences were
considered significant when p<0.05. The analysis was performed
using JMP (version 9) software. 
The significance of the difference in the mean SLFN11
expression levels according to decitabine treatment at each
timepoint was analyzed using the Dunnett test. The significance
of the difference in the mean TV between the 2 groups on day 15
was analyzed using the Aspin-Welch two-tailed t-test. Differences
were considered significant when p<0.05. The analyses were
performed using EXSUS version 8.0 software (CAC Croit Corp.,
Tokyo, Japan).
Results
Antitumor activity of trabectedin in 30 human sarcoma cell
lines. To evaluate the antitumor activity of trabectedin in
sarcoma cell lines, the IC50 of trabectedin was determined in
both translocation related sarcoma (TRS) cell lines, which
contain gene fusions, and in non-TRS cell lines using an in
vitro cell viability assay. Trabectedin showed nanomolar
ranges of IC50 values in both TRS and non-TRS cell lines,
and the ranges of all the IC50 values were extremely narrow
(Figure 1). 
Expression level of SLFN11 was positively correlated with
the antitumor activity of trabectedin. To determine the
relationship between the SLFN11 expression levels and the
sensitivity to trabectedin in 30 sarcoma cell lines, the
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Figure 1. Trabectedin shows a significant antitumor activity in sarcoma cell lines. Thirty sarcoma cell lines were exposed to trabectedin for 72 h.
Nine TRS cell lines (solid black bars) and 21 non-TRS cell lines (hashed bars) were used. The error bars represent the standard deviation (SD, n≥3).
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Figure 3. Antitumor activity of trabectedin was decreased in SLFN11-
knockdown cells. Transfection using control siRNA (siControl) and
SLFN11 siRNA (siSLFN11) was performed in the indicated cell lines.
The viability curves for the indicated cell lines after continuous
treatment with trabectedin for 72 h are shown. The viability of untreated
cells was set at 100%. The error bars represent the standard deviation
(SD, n≥3). (a) SW 872 is a liposarcoma cell line (non-TRS). (b) A673
is a Ewing’s sarcoma cell line (TRS). (c) SK-ES-1 is a Ewing’s sarcoma
cell line (TRS).
Figure 2. Antitumor activity of trabectedin was correlated with SLFN11 expression levels. (a) Correlation between SLFN11 expression (mRNA
expression level of SLFN11=[2–ΔCt] ×1000, ΔCt=[Ct of SLFN11] – [mean of Cts of ACTB and GAPDH]) and −log2IC50 of trabectedin across
sarcoma cell lines. Correlation coefficients: r=0.479, p<0.01. (b) No significant difference in SLFN11 expression was seen between the TRS and
non-TRS cell lines. p=0.1203.
correlation between the antitumor activity (–log2IC50) of
trabectedin and the SLFN11 expression levels was
determined using quantitative PCR in each cell line. The
expression level of SLFN11 was positively correlated with
the antitumor activity of trabectedin, and cell lines with high
levels of SLFN11 expression were more sensitive to
trabectedin (correlation coefficients: r=0.479, p<0.01)
(Figure 2a). Furthermore, no significant difference was seen
in the gene expression levels of TRS and non-TRS cell lines
(Figure 2b).
Differences in antitumor activity of trabectedin between high
and low SLFN11 expression cells. To determine the causal
relation of SLFN11 and trabectedin sensitivity, SLFN11 was
knocked down using siRNA in three high SLFN11 expressing
cell lines (liposarcoma SW 872, Ewing’s sarcoma A673 and
SK-ES-1) and determined the IC50 and IC75 values using cell
viability assays. All three SLFN11-knockdown cell lines had
a lower sensitivity to trabectedin than the control cells,
which were treated with negative control siRNA (siControl).
The IC50 and IC75 values of the knockdown cells were 3.4
and 2.8 fold (SW 872), 1.8 and 2.2-fold (A673), and 2.6 and
3.6-fold (SK-ES-1) higher than those of each control group,
respectively (Figure 3a, b, c).
Furthermore, the SW 872 and A673 cell lines, which were
transfected with siSLFN11 and siControl cells, were exposed
to 20 nmol/l of trabectedin for 1 h, followed by 48 h post-
incubation in drug-free media. The phosphorylation of
checkpoint kinase 1 (CHK1) on Ser317 and Ser345 residues
after trabectedin exposure were observed in both cells
independently of SLFN11 expression levels. On the other
hand, CHK1 expression was reduced in the high SLFN11
expression cells. Additionaly, the phosphorylation of Histone
H2A.X after trabectedin exposure was lower in the SLFN11-
knockdown cells, compared with high SLFN11 expression
cells (Figure 4).
Quantitative PCR analysis indicated that the U-2 OS
(osteosarcoma) cell line expressed minimal levels of
SLFN11. In public data from the CellMiner portal site
(https://discover.nci.nih.gov/cellminercdb/), the SLFN11 gene
was hypermethylated in the U-2 OS cell line, compared with
other high SLFN11 expression sarcoma cell lines (Figure 5a).
Furthermore, treatment of the U-2 OS cell line with 1 μmol/l
decitabine restored the SLFN11 expression levels (Figure
5b). To determine whether a DNA methyltransferase
inhibitor enhances the trabectedin antitumor activity in
SLFN11-hypermethylated cells, the U-2 OS cell line was
exposed to 1 μmol/l of decitabine for 24 h before adding
trabectedin for 72 h and assaying cell viability. The IC50
value of decitabine in combination with trabectedin was
approximately 2-fold lower than that of trabectedin alone
(Figure 5c).
ATR inhibitor enhanced the antitumor activity of trabectedin
in SLFN11-knockdown cells. Because SLFN11 blocks
replication regardless of ATR-CHK1 activity (22), in low
SLFN11 expression cells, DNA damage response might be
dependent on ATR. Therefore, the combined antitumor activity
of an ATR inhibitor (VE-821) and trabectedin was evaluated.
SW 872 and A673 cell lines, which were transfected with
siSLFN11 or siControl, were exposed to 1 μmol/l of VE-821
and trabectedin for 72 h (Figure 6a and b). As a result, VE-
821 enhanced the antitumor activities of trabectedin by 2-fold
in the two SLFN11-knockdown cell lines.
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Figure 4. DNA damage checkpoint was activated by trabectedin in SLFN11-knockdown cells. SW 872 and A673 cells, which were transfected with
siControl and siSLFN11, were exposed for 1 h with trabectedin (20 nmol/l) followed by 24 and 48 h post-incubation in drug-free media, as indicated.
The phosphorylation of CHK1 was upregulated in all cell lines, and CHK1 was degradated in the control cells.
ATR inhibitor enhanced the antitumor activity of trabectedin in
a SLFN11-knockout SW 872 xenograft model. Next, the
combined antitumor activity of trabectedin and ATR inhibitor
(VE-822) was examined in xenograft nude mice models of SW
872 and SLFN11-knockout SW 872 (Figure 7a and b). The
SLFN11 protein expression levels in each SW 872 tumor
fragment used in this study were examined by western blotting
(Figure 7c). Mice were treated with trabectedin at 0.1
mg/kg/day (dosed by intraperitoneal bolus injection on days 1,
5, and 9) and VE-822 at 30 mg/kg/day (dosed by oral gavage
on days 1, 2, and 3 of each 4-day cycle) or a combination of
both agents together. Trabectedin monotherapy induced
significant antitumor activity (83% TGI) in the high SLFN11
expression SW 872 xenograft model on Day 15. Although
trabectedin monotherapy had marginal antitumor activity (37%
TGI) in the SLFN11-knockout SW 872 xenograft model, the
combination with VE-822 induced a higher antitumor activity,
compared with trabectedin monotherapy. The combination was
well tolerated, and no increase in body weight loss was
observed compared with trabectedin monotherapy.
Discussion
To clarify the role of SLFN11 in the antitumor mechanism
of trabectedin, the relation between SLFN11 expression
levels and the antitumor activities of trabectedin were
evaluated. We demonstrated, for the first time, the role of
SLFN11 in cellular responses to trabectedin. Our study
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Figure 5. Demethylation of SLFN11 enhanced the antitumor activity of trabectedin. (a) SLFN11 expression in the cancer cell lines of the CCLE collection
matched with promoter methylation determined from data obtained from the GDSC database for individual common cell lines across the two databases
(blue dots) obtained using CellMiner (http://discover.nci.nih.gov/cellminercdb/). The U-2 OS cell line does not express SLFN11 and exhibits promoter
methylation; the U-2 OS cell line is marked in red. (b) The expression of the SLFN11 RNA transcript was restored in the methylated U-2 OS cell line
by treatment with the demethylating drug 5-aza-2’-deoxycytidine (DAC, decitabine). n.s: Not significant, ***p<0.001. (c) Viability curves of the indicated
cell lines after continuous treatment for 72 h with trabectedin alone (blue) and after exposure to 1 μmol/l of decitabine for 24 h before the addition of
trabectedin (red). The viability of untreated cells was set at 100%. The error bars represent the standard deviation (SD, n≥3). 
showed that trabectedin had an IC50 in the nanomolar range
in both TRS and non-TRS cell lines, and SLFN11 expression
was correlated with sensitivity to trabectedin. The antitumor
mechanism of trabectedin through the function of SLFN11
seems to act independently of fusion genes. Therefore, we
focused on the role of SLFN11 in the antitumor activities of
trabectedin.
In this study, SLFN11-knockdown cell lines and a
xenograft model of SLFN11-knockout cells showed a lower
sensitivity to trabectedin, compared to their parental high
SLFN11 expression cells, in vitro and in vivo, respectively.
In aggremment, the sensitivities to other DNA-damaging
anticancer drugs such as topotecan, irinotecan, and cisplatin
are also reportedly linked to SLFN11 expression (19). On the
other hand, SLFN11 expression did not exhibit any
association with the response to drugs targeting other
components, such as paclitaxel (data not shown). Since the
enhancement of the antitumor activities through the
modification of SLFN11 expression levels seems to be
specific to DNA-damaging anticancer drugs (19), we
hypothesized that SLFN11 might be involved in DNA repair.
Although one group has reported a significant combined
antitumor activities of trabectedin and ATR inhibitors in
ovarian cancer cell lines (23), our results demonstrated that
an ATR inhibitor enhanced the antitumor activity of
trabectedin in SLFN11-knockdown cell lines in vitro and in
SLFN11-knockout tumors in vivo. The above study showed
that the ATR/CHK1 and ATM/CHK2 pathways were
activated in response to trabectedin, and that the dual
inhibition of ATR and ATM increased the antitumor activity
of trabectedin. Furthermore, lack of SLFN11 expression is a
major cause of resistance to PARP inhibitors, and addition
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Figure 6. ATR inhibitor enhanced the antitumor activity of trabectedin in SLFN11-knockdown sarcoma cells in vitro. High SLFN11 expression (a) SW
872 and (b) A673 cell lines transfected with siControl (upper) or siSLFN11 (lower) were exposed to trabectedin alone or a combination of 1 μmol/l of
VE-821 and trabectedin for 72 h. The viability of untreated cells was set at 100%. Error bars represent the standard deviation (SD, n≥3).
of an ATR inhibitor overcomes such resistance (24). On the
other hand, the antitumor mechanism of trabectedin does not
necessarily involve only DNA-damaging effects, but other
effects such as the suppression of transcription factors, cell-
cycle regulation, or tumor microenvironment regulation
might also be involved (10, 16, 25). Therefore, SLFN11-
knockdown cell lines did not show resistance to trabectedin,
but rather exhibited a lower sensitivity to trabectedin, unlike
other DNA-damaging anticancer drugs.
In addition, a previously reported analysis of DNA
methylation using the cancer cell line panel NCI60 has
identified SLFN11 CpG promoter island hypermethylation as
a predictive biomarker of platinum resistance (18, 26). Some
studies have revealed that the DNA methyltransferase
ANTICANCER RESEARCH 39: 3553-3563 (2019)
3560
Figure 7. ATR inhibitor enhanced the antitumor activity of trabectedin in SLFN11-knockout sarcoma xenografts in vivo. A mouse xenograft
experiment using (a) SW 872 (high SLFN11 expression) and (b) SLFN11-knockout SW 872 cell lines was performed. Mice bearing tumors were
treated with the vehicle (dosed on days 1, 5, and 9), trabectedin (dosed on days 1, 5, and 9), VE-822 (dosed on days 1, 2, and 3 of each 4-day
cycle), or a combination of both drugs. The tumor volume (TV, left) and the relative body weight change (BWC, right) were plotted. The error bars
represent the SE (n=6). n.s: Not significant, **p<0.01. (c) The lack of SLFN11 protein expression in the SLFN11-knockout SW 872 tumor fragments
used in this study was examined using western blotting.
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Figure 8. Speculated mechanism of the combined effect of trabectedin and an ATR inhibitor, berzosertib, or a DNA methyltransferase inhibitor,
decitabine, in low-SLFN11 expression cells. (a) In high-SLFN11 expression cells, when trabectedin is added to the cells, SLFN11 might block
replication (22). Therefore, trabectedin has a high antitumor activity in these cells. (b) On the other hand, DNA damage response might be
dependented on ATR in low-SLFN11 expression cells, the inhibition of the DNA repair system by the ATR inhibitor berzosertib leads to enhancement
of the antitumor activity of trabectedin. (c) The restoration of SLFN11 expression by the DNA methyltransferase inhibitor decitabine also leads to
enhancement of the antitumor activity of trabectedin. Therefore, a combination therapy of trabectedin and berzosertib or decitabine is promising
against low-SLFN11 expression tumors.
inhibitor and the EZH2 inhibitor induce SLFN11 expression
in several cancer cell lines (18, 27). Induction of SLFN11
expression by decitabine in a sarcoma cell line and the
enhancement of the antitumor activity of trabectedin by
combination with decitabine were observed in the present
study. These results suggest that combination treatment
consisting of DNA methyltransferase inhibitor and DNA-
damaging anticancer drugs, including trabectedin, could be
a promising treatment against SLFN11-hypermethylated cells
(Figure 8).
Recently, Murai et al. have shown that SLFN11 is
recruited to stressed replication forks carrying extended RPA
filaments where it blocks replication by changing the
chromatin structure across replication sites independently of
HRR (22). This might be the reason why the antitumor
activity of trabectedin in high SLFN11 expression cells
shows a higher sensitivity to trabectedin, compared with
SLFN11-deficient cells. Furthermore, the report suggests that
in a DNA repair system, such as HRR, DNA damage
response might be dependented on ATR in low SLFN11
expression cells, and the combination of DNA-damaging
anticancer drugs including trabectedin and ATR inhibitors
seems promising against SLFN11-deficient cells (Figure 8).
The present study suggests the importance of SLFN11
expression as a key factor in the antitumor activity of
trabectedin. Furthermore, the combination of trabectedin and
an ATR inhibitor or DNA methyltransferase inhibitor was
useful against SLFN11-deficient cells, in which trabectedin
has a low antitumor activity.
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